If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis—a condition where stomach emptying slows. This page draws on established medical understanding of drug side effects to help you recognize key symptoms and know when to seek care. Here we outline the clinical context and monitoring steps.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known adverse effects, gastrointestinal reactions are prominent. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis often involves gastric emptying scintigraphy or breath tests. The mechanistic pathways linking GLP-1 receptor agonists like Ozempic to gastroparesis involve the drug's effect on gastric motility. GLP-1 agonists slow gastric emptying, which is part of their therapeutic action for glycemic control, but this effect can become pathological, leading to gastroparesis in susceptible individuals. The reported gastrointestinal adverse reactions with Ozempic include dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
While gastroparesis is not explicitly listed as a separate adverse reaction in the provided label data, the constellation of symptoms and the known pharmacodynamic effect support a plausible association. The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The Ozempic label includes warnings about gastrointestinal adverse reactions and hypersensitivity, including serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not specifically warn about gastroparesis as a distinct condition. This gap may affect the adequacy of warnings for patients who develop severe or persistent symptoms consistent with gastroparesis. For affected patients, settlement-related considerations depend on the timeline between exposure and documented harm. The gastrointestinal adverse reactions in clinical trials were most common during dose escalation, suggesting that early symptoms may be a signal for later development of gastroparesis. Patients who experienced prolonged nausea, vomiting, or other symptoms after starting Ozempic and later received a formal diagnosis of gastroparesis may have a stronger claim if the timeline is consistent with drug exposure. In New Jersey, the statute of limitations for product liability claims, including those related to inadequate warnings, is generally two years from the date the injury was discovered or should have been discovered. For gastroparesis associated with Ozempic, this means that patients must file a claim within two years of recognizing that their symptoms were caused by the drug. The timeline between exposure and harm is critical: if a patient started Ozempic and developed symptoms within weeks or months, the clock may start from the date of diagnosis or from when a reasonable person would have connected the symptoms to the medication. Given that gastrointestinal adverse reactions are common and often resolve with dose adjustment, distinguishing transient effects from chronic gastroparesis is essential. Patients who discontinued Ozempic due to gastrointestinal issues but later developed persistent symptoms should document the timeline carefully. Settlement-related considerations also involve the strength of evidence linking Ozempic to gastroparesis. While the label data show increased gastrointestinal adverse reactions, including dyspepsia and GERD, which are components of gastroparesis, direct evidence of gastroparesis as a specific adverse reaction is not provided in the available snippets. This may affect the ability to prove causation in individual cases. However, the mechanistic plausibility and the higher rates of gastrointestinal adverse reactions in Ozempic-treated patients compared to placebo support a potential link. Patients considering legal action should consult with a medical expert to establish the diagnosis and timeline. In summary, the evidence from the Ozempic label indicates a clear association with gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The adequacy of warnings is questionable because gastroparesis is not specifically mentioned. In New Jersey, the statute of limitations requires prompt action after discovery of harm. Patients should document their exposure, symptoms, and diagnosis to support any potential claim. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In New Jersey, the statute of limitations for product liability claims, including those related to inadequate warnings, is generally two years from the date the injury was discovered or should have been discovered. For gastroparesis associated with Ozempic, this means patients must file a claim within two years of recognizing that their symptoms were caused by the drug.
No, the Ozempic label does not specifically warn about gastroparesis as a distinct condition. It includes warnings about gastrointestinal adverse reactions and hypersensitivity, but gastroparesis is not explicitly mentioned. This gap may affect the adequacy of warnings for patients who develop severe or persistent symptoms consistent with gastroparesis.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Ozempic exposure and a related diagnosis may request an independent, no-cost eligibility review.